Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Millendo Therapeutics, Inc. SEC-Registered At-The-Market Offering Program
Davis Polk advised a sales agent in connection with the establishments of an SEC-registered at-the-market offering program…
NanoString Technologies, Inc. Follow-on Offering
Davis Polk advised the joint book-running managers and the lead manager in connection with a $119 million public…
Davis Polk Advises ShockWave Medical, Inc. on Its $111.4 Million Initial Public Offering
Davis Polk advised ShockWave Medical, Inc. on its SEC-registered initial public offering of 6,555,000 shares of common stock…
Horizon Pharma Follow-On Offering
Davis Polk advised the underwriters in connection with the $345 million public offering of ordinary shares of Horizon Pharma…
Medtronic Global Holdings S.C.A. €7 Billion Notes Offering
Davis Polk advised the representatives of the several underwriters in connection with an SEC-registered offering of €7…
Merck $5 Billion Notes Offering
Davis Polk advised the representatives of the underwriters in connection with the offering of $5.0 billion aggregate…
Davis Polk Advises CStone Pharmaceuticals on Its HK$2.24 Billion (US$285.05 Million) Initial Public Offering
Davis Polk advised CStone Pharmaceuticals in connection with its initial public offering and listing on the Hong Kong Stock…
Davis Polk Advises Roche on Its Acquisition of Spark Therapeutics
Davis Polk is advising Roche on its approximately $4.3 billion acquisition of Spark Therapeutics, Inc. The transaction,…
Eli Lilly $4.5 Billion Notes Offering
Davis Polk advised the joint book-running managers in connection with a $4.5 billion registered offering by Eli Lilly and…
Pernix Enters into an Agreement for the Sale of Substantially All of Its Assets Subject to a Competitive Bidding Process and Files for Chapter 11
Davis Polk is advising Pernix Therapeutics Holdings, Inc. in connection with its restructuring under chapter 11 of the…